Medtronic received information via literature from pediatrics spanish registry on percutaneous melody pulmonary valve implantation in patients younger than 18 years.All data were collected from multiple centers between march 2007 and january 2017.Eighty one medtronic melody valves were implanted in 77 patients (predominantly male, median age 13 years).One patient underwent a double implantation because he had a double right ventricular outflow tract (rvot) (conduit + native rvot) and 3 patients required a second melody valve (2 via the valve-in-valve technique and the other after explantation of the initial valve and surgical reconstruction of the rvot).One patient had a previously implanted contegra valved conduit.No serial numbers were provided.Among all patients, 1 death occurred due to infective endocarditis.The time from implant to infection was not clearly stated for this patient; however, per table 4 the shortest time frame could have been 100 days post-implant.Insufficient information received to reasonably suggest that the device caused/contributed to a reportable event.Among all patients, adverse events included: iatrogenic aortopulmonary window and tricuspid valve injury requiring intervention, moderate tricuspid regurgitation, ventricular tachycardia, mild paravalvular leak (pvl), pulmonary edema, severe pulmonary regurgitation requiring reintervention with balloon dilation, or valve-in-valve, endocarditis requiring surgical extraction of the valve.Based on the available information, medtronic product may have caused or contributed to these adverse events.Among all patients, adverse events related to ensemble delivery system included: femoral thrombosis.Among all patients, adverse events related to contegra included: endocarditis.Among all patients, device malfunctions related to melody included: stent fracture.Based on the available information, this malfunction may have been attributed to medtronic product.No additional adverse patient effects or product performance problems were reported.
|